Supplement GMP Documentation Better, But Still No. 2 On FDA Observation List – AHPA
FDA revisits about a third of supplement manufacturing sites, with two-thirds coming within three years, says AHPA. Chief information analyst Merle Zimmermann says FDA increased focus on recordkeeping has resulted in an improvement and fewer problems reported since 2015
You may also be interested in...
The US Food and Drug Administration directs Marco Pharma International to correct GMP compliance issues identified during a May 2019 site inspection, including quality control and recordkeeping failures, in a warning letter made public 4 February.
Cross Brands violated GMP including verifying the identity of ingredients and made acne- and eczema-treatment label claims for products not covered under the OTC drug monograph, says FDA in a warning letter.